Loading
A chemotherapy-free bispecific plus ADC doublet beat salvage chemotherapy in relapsed large B-cell lymphoma.
SUNMO, trial NCT05171647 sponsored by Roche and reported in 2025, showed that a chemotherapy-free doublet of the CD20 bispecific mosunetuzumab and the CD79b antibody-drug conjugate polatuzumab vedotin beats rituximab-gemcitabine-oxaliplatin salvage chemotherapy in relapsed or refractory large B-cell lymphoma in transplant-ineligible patients. It randomised 208 patients and met its dual primary endpoints of progression-free survival and overall response, with a much higher complete response rate, in a fixed-duration outpatient regimen. OnCo links it to lymphoma, mosunetuzumab, polatuzumab vedotin and the pairing of a CD20 bispecific with a CD79b ADC. Overall survival is not yet mature, and whether the doublet is an alternative for patients not fit for CAR-T or a competitor to it is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
208 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (dual primary)primary | Mosunetuzumab + polatuzumab vedotin | 138 | 11.5 months | 0.41 (0.3 to 0.6) | <0.0001 | link |
| R-GemOx | 70 | 3.8 months | ||||
| Overall response rate (dual primary)primary | Mosunetuzumab + polatuzumab vedotin | - | 70% | - | <0.0001 | link |
| R-GemOx | - | 40% | ||||
| Complete response rate | Mosunetuzumab + polatuzumab vedotin | - | 51% | - | - | link |
| R-GemOx | - | 24% |
Shares Polatuzumab vedotin, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one, POLARGO, Roche / Genentech, T-cell engagers (bispecific).
Shares Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one, POLARGO, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab), Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares POLARGO, Polatuzumab vedotin, Roche / Genentech, Diffuse large B-cell lymphoma.